J. C. Dawson

A targetable PREX2/RAC1/PI3Kβ signalling axis confers resistance to clinically relevant therapeutic approaches in melanoma

This study identifies a druggable PREX2/RAC1/PI3Kβ signalling axis in BRAF-mutant melanoma that confers resistance to therapies and can be targeted to improve treatment outcomes.

A novel ILK/STAT3 pathway controls plasticity in a neural stem cell model of glioblastoma.

This study identifies a novel ILK-STAT3 pathway that regulates phenotypic plasticity and mesenchymal state in mouse glioblastoma stem cells.

The first two chromosome-scale genome assemblies of American hazelnut enable comparative genomic analysis of the genus Corylus

This paper presents the first chromosome-scale genome assemblies of American hazelnut, enabling structural variation analysis and phylogenetic studies of self-incompatibility in the Corylus genus.

Discovery of new senolytics using machine learning

This paper uses machine learning to discover three new senolytic compounds by screening FDA-approved drugs and clinical candidates.

Characterisation of a nucleo-adhesome

The paper identifies a nucleo-adhesome, showing that adhesion proteins localize to the nucleus and regulate transcription through interactions like FAK and Hic-5.

Pathway profiling of a novel SRC inhibitor, AZD0424, in combination with MEK inhibitors.

This study profiles the effects of the SRC inhibitor AZD0424 in combination with MEK inhibitors, showing reduced compensatory activation and enhanced anti-tumor effects in colorectal cancer models.

11β-HSD1 inhibition does not affect murine tumour angiogenesis but may exert a selective effect on tumour growth by modulating inflammation and fibrosis

This study investigates the effect of 11β-HSD1 inhibition on tumour growth and angiogenesis in murine models, finding increased SCC tumour growth but no effect on angiogenesis.

A Synergistic Anti-Cancer FAK and HDAC Inhibitor Combination Discovered by a Novel Chemical-Genetic High Content Phenotypic Screen

The paper identifies a synergistic combination of FAK and HDAC inhibitors using a chemical-genetic high-content screen, showing efficacy in cancer cell lines and in vivo.